Evidence map›Paper›PMID 40825555›Full record

ArticleThe Journal of infectious diseases2026

Population Structure of Escherichia coli Isolated From the Human Bloodstream, Human and Animal Feces, and the Environment in Northern Tanzania.

Deng B Madut, Matthew P Rubach, Flemming Scheutz, Douglas R Call, Firdoos A Gogry, Manuela Carugati, Nathaniel Kalengo, Annette Marandu, Michael J Maze, Anne B Morrissey and 5 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. High clonal diversity, resistome, and virulome ofFrontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Deng B MadutDivision of Infectious Diseases and International Health, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-4023-3928
Matthew P RubachDivision of Infectious Diseases and International Health, Duke University, Durham, North Carolina, USA.ORCID 0000-0001-5262-1421
Flemming ScheutzInternational Centre for Reference and Research on Escherichia and Klebsiella, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0002-3931-4846
Douglas R CallPaul G. Allen School for Global Health, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.
Firdoos A GogryPaul G. Allen School for Global Health, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.
Manuela CarugatiDivision of Infectious Diseases and International Health, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-3187-5905
Nathaniel KalengoKilimanjaro Christian Medical Centre, Moshi, Tanzania.
Annette MaranduMawenzi Regional Referral Hospital, Moshi, Tanzania.
Michael J MazeDepartment of Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0001-8909-1508
Anne B MorrisseyDivision of Infectious Diseases and International Health, Duke University, Durham, North Carolina, USA.
Bingileki F LwezaulaMawenzi Regional Referral Hospital, Moshi, Tanzania.ORCID 0000-0003-2909-9705
Blandina T MmbagaKCMC University, Moshi, Tanzania.
Kajiru G KilonzoKCMC University, Moshi, Tanzania.
Venance P MaroKCMC University, Moshi, Tanzania.
John A CrumpCentre for International Health, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-4529-102X

Funding

Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
Vanderbilt-Emory-Cornell-Duke Global Health Fellowship Consortium-Expanding Diversity for Global Equity (EDGE)D43TW009337 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, HEIMBURGER, DOUGLAS CORBETT · 2017 to 2021
$6.3M
International Clinical Trials UnitU01AI062563 · NIAID · DUKE UNIVERSITY · PI BARTLETT, JOHN A · 2004 to 2007
$4.0M
Investigating Febrile Deaths in Tanzania (INDITe)R01AI121378 · NIAID · DUKE UNIVERSITY · PI RUBACH, MATTHEW P · 2016 to 2020
$2.7M
The Impact and Society Ecology of Bacterial Zoonoses in Northern Tanzania: UnderR01TW009237 · FIC · DUKE UNIVERSITY · PI CRUMP, JOHN ANDREW · 2011 to 2014
$1.7M
Viral Zoonoses and Severe Febrile Illness in Northern TanzaniaK23AI116869 · NIAID · DUKE UNIVERSITY · PI RUBACH, MATTHEW P · 2016 to 2020
$896k
Transmission dynamics and epidemiology of Rift Valley fever virus in northern TanzaniaK08AI182480 · NIAID · DUKE UNIVERSITY · PI Deng Buok Madut · 2024 to 2026
$483k
Bill & Melinda Gates FoundationFIC NIH HHS D43 TW009337FIC NIH HHS R01 TW009237NIAID NIH HHS K08 AI182480NIAID NIH HHS K23 AI116869NIAID NIH HHS R01 AI121378NIAID NIH HHS T32 AI007392NIAID NIH HHS U01 AI062563Typhoid Fever Surveillance in sub-Saharan Africa Program 5T32AI007392Typhoid Fever Surveillance in sub-Saharan Africa Program D43TW009337Typhoid Fever Surveillance in sub-Saharan Africa Program K08AI182480Typhoid Fever Surveillance in sub-Saharan Africa Program OPPGH5231UK Research and Innovation BB/J010367/1UK Research and Innovation BB/K01126X/1UK Research and Innovation BB/L017679UK Research and Innovation BB/L018845UK Research and Innovation BB/L018926UK Research and Innovation BB/L018926/1UK Research and Innovation MC_UU_12014/9US National Institutes of HealthUS National Science Foundation DEB1216040US NIH K23AI116869US NIH R01AI121378US NIH U01AI062563(US NIH)-National Science Foundation Ecology of Infectious Disease program R01TW009237
6 · The paper itself

Abstract

backgroundExtraintestinal pathogenic Escherichia coli (ExPEC) are a leading cause of human bloodstream infections (BSIs) in sub-Saharan Africa, yet few studies have characterized African strains implicated in BSI or explored their potential reservoirs.

methodsWe enrolled febrile patients at 2 hospitals in Moshi, Tanzania, 2007-2019, and performed blood cultures. Whole-genome sequencing was conducted on E. coli originating from the bloodstream to characterize sequence types (STs), serotypes, and theoretical coverage of a 9-valent ExPEC polysaccharide conjugate vaccine (ExPEC9V). Separately, we evaluated 601 E. coli whole-genome sequences from humans, animals, and environmental sources in nearby communities. We assessed genetic relatedness between bloodstream and community isolates based on single-nucleotide polymorphisms and allele differences.

findingsOf 3046 participants receiving blood culture, 48 (0.2%) had BSI yielding 48 E. coli isolates. The median (range) age of participants with E. coli BSI was 40.7 (0.3-89.0) years, and 32 (68.1%) were female. We identified 16 STs including ST131 (n = 16, 33.3%), ST73 (n = 10, 20.8%), and ST69 (n = 6, 12.5%) and 19 O groups including O25 (n = 13, 27.1%), O6 (n = 10, 20.3%), O17 (n = 4, 8.3%), and O18 (n = 4, 8.3%). Theoretical coverage for an ExPEC9V was 72.9%. None of the bloodstream and community E. coli pairs were closely related.

conclusionsWe found a high diversity of STs among E. coli human bloodstream isolates in Tanzania. Despite this diversity, we observed that an EXPEC9V in development would provide good coverage. Reservoir-attribution studies at finer spatial and temporal scales may better identify transmission networks and reservoirs of ExPECs.

Indexed as

BacteremiaEscherichia coliEscherichia coli InfectionsFecesAdolescentAdultAgedAged, 80 and overAnimalsChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedAfricabacteremiaEscherichia coliTanzaniawhole-genome sequencing

Identifiers

PMID40825555
PMCPMC12811864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.